Danaher's first quarter 2026 EPS beats by 6% while the company raises full-year guidance.

Danaher reported first quarter 2026 revenue of $6.0 billion, in line with analyst expectations, and non-GAAP adjusted EPS of $2.06, beating estimates of $1.94 by 6.2%.

Key Highlights

• The company raised its full-year 2026 adjusted EPS guidance to a new range of $8.35 to $8.55, up from the previous range of $8.35 to $8.50.
• Non-GAAP core revenue grew 0.5% year-over-year, driven by 7.0% core growth in the Biotechnology segment and 0.5% in Life Sciences, which offset a 4.0% decline in Diagnostics.
• Danaher generated non-GAAP free cash flow of $1.1 billion during the quarter, based on operating cash flow of $1.3 billion.